Enliven Therapeutics, Inc.

Historical 13F Holders

Symbol
ELVN
CUSIP
29337E102
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 29337E102 since 12/18/2024, largest first.

Filer % of Class Filed
FMR LLC 13G/A
15.0% 8/6/2026
Event 6/30/2026
Orbimed Advisors LLC 13D/A
9.5% 6/24/2026
Event 6/22/2026
Polar Capital Holdings Plc 13G/A
8.5% 6/22/2026
Event 3/31/2026
Commodore Capital LP 13G/A
7.7% 5/15/2026
Event 3/31/2026
BlackRock, Inc. 13G/A 7.1% 10/27/2026
Event 9/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (3)
Vestal Point Capital, LP 13G/A
4.4% 11/16/2026
Event 9/30/2026
Fairmount Funds Management LLC 13G/A
3.1% 5/15/2026
Event 3/31/2026
Venrock Healthcare Capital Partners III, L.P. 13G/A
2.8% 5/15/2026
Event 3/31/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 220 82.6 M $3.79B
2026 Q2 215 80.2 M $4.06B
2026 Q1 174 62.8 M $2.44B
2025 Q4 128 62.4 M $961M
2025 Q3 135 59.4 M $1.22B
2025 Q2 127 59.4 M $1.19B
2025 Q1 124 49.9 M $984M
2024 Q4 116 49.6 M $1.12B
2024 Q3 104 47.7 M $1.22B
2024 Q2 96 48.3 M $1.13B
2024 Q1 75 44.5 M $781M
2023 Q4 63 39.0 M $540M
2023 Q3 63 39.1 M $534M
2023 Q2 64 39.1 M $798M
2023 Q1 45 33.6 M $735M